Chronic rhinosinusitis: An under-researched epidemic

Abstract

Background

Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory disease with significant impacts on patient quality of life and daily productivity. Evaluating the volume of research on CRS, relative to similar chronic diseases, may provide insight into current disparities in research prioritization.

Methods

A systematic review was performed using Ovid MEDLINE (R) (1970 – December 31st, 2014) to define the volume of research publications for CRS, asthma, and diabetes mellitus (DM). Primary outcomes were overall volume of research publications and volume of publications per year. A subgroup analysis was performed using chi-square (χ2) omnibus test with 2×3 contingency tables to identify significant differences in the proportion of total randomized controlled trials, systematic reviews, meta-analyses, and economic evaluation publications between CRS, asthma, and DM groups.

Results

There were substantial disparities in the volume of research published over the last 45 years for CRS (n = 7,962), asthma (n = 136,652), and DM (n = 337,411). Although the volume of research for CRS in increasing, the disparities in the annual publication volumes between CRS, asthma, and DM appeared consistent over the last 45 years.

Conclusions

Outcomes from this review have demonstrated a large disparity in the volume of published research for CRS compared to asthma and DM. Given the similarities in prevalence rates, impact on quality of life and economic burden, the relative under supply of CRS research should prompt efforts to increase research prioritization for this chronic disease.

Keywords

Chronic sinusitis Rhinosinusitis Burden of disease Research prioritization Publication volume

Background

The advancement of medical knowledge with subsequent translation into real world improvements is a key mandate for several stakeholders in health care [1-3]. Peer-reviewed publication is an essential vehicle to share newly acquired knowledge, and without publication of high quality research, advancements in the quality of care will be limited. Since there are scarce resources to support medical research, it is important to prioritize resources toward the highest impact diseases, however, due to the large number of different stakeholders involved in health care, research prioritization is a very complex process [4]. Several factors influence research priority setting, however, one important factor is the estimated burden of disease [5-7].

Chronic rhinosinusitis (CRS) not only represents one of the most prevalent chronic diseases in developed countries [8] but also represents a substantial burden of disease on patient quality of life [9], productivity [10], and health care spending [11]. Based on the best available evidence, the prevalence of CRS in North America and Europe likely falls within the range of 5% and 12% [12-14] which rivals and potentially exceeds that of other common chronic diseases such as asthma and diabetes mellitus (DM) (Table 1) [12,15-18]. If research prioritization accurately reflects burden of disease, then the volume and quality of publications should be somewhat similar between diseases with similar burden of disease.

Table 1

Geographic prevalence rates per chronic disease

Chronic disease	Prevalence
	Canada	US	Europe/UK	Mean
CRS	5.7% [13]	12.1% [12]	10.9% [14]	9.6%
Asthma	7.9% [15]	8% [12]	3.8% [16]	6.6%
DM	6.6% [17]	8.6 [12]	6.4% [18]	7.2%

US, United States; UK, United Kingdom; CRS, chronic rhinosinusitis; DM, diabetes mellitus.

The primary objective of this review is to evaluate how the volume of research publications for CRS has changed over the last 45 years and compare the volume of research to asthma and DM. The secondary objective is to evaluate the differences in high-quality publications between each of the chronic diseases. The purpose of this study is to identify potential disparities in research output for CRS, compared to similar chronic diseases, which may be used to improve future research priority setting.

Methods

The three comparator groups in this review include: CRS, asthma, and DM (both type I and II). Asthma and DM were chosen as comparators due to their similar chronic disease state (often requiring life-long medical therapy) as well as their similar prevalence rates [12-18] and impact on quality of life [9,19,20]. A literature search was performed in December 2014 using Ovid MEDLINE (R) (1970 - December 2014) to define the volume of research publications for CRS, asthma, and DM. The following search terms were used to identify published literature for CRS (terms: ‘chronic’ AND ‘*sinusitis’), asthma (term: ‘asthma’), and DM (terms: ‘diabetes’ AND ‘mellitus’). An unlimited truncation strategy (placement of *) was used to capture all variations of key disease related terms.

After the overall volumes of publications were obtained, limitations for randomized controlled trials (RCTs), systematic reviews (SRs), and meta-analyses (MAs) were applied to separate the overall volume of publications into sub groups. The National Institute for Health Research Economic Evaluation Database (NHS EED) was searched using the same key terms to identify the volume of economic evaluations (EEs) published for each chronic disease. A chi-square (χ2) omnibus test with 2x3 contingency tables was performed to identify significant differences in the proportion of total RCT, SR, MA, and EE publications between CRS, asthma, and DM groups. Significant global tests were followed with bivariate subgroup testing was complete to identify differences between CRS, asthma, and DM groups.

Results

Volume of publications

The literature review demonstrated large disparities in volume of publications between CRS, asthma, and DM (Table 2). There were 1,171 articles that overlapped with both CRS and asthma, which represented 15% of the CRS volume and 0.9% of the asthma volume. When evaluating the proportion of research dedicated to high-level evidence (ie. RCTs, SRs, MAs, and EEs), there were differences in the proportions of RCTs, SRs, and MAs published between groups (all <0.018)(Table 2).

Table 2

Publications per chronic disease between 1970 -2014

Chronic disease	Crude number of publications	RCTs (% of total publications)	SRs (% of total publications)	MAs (% of total publications)	EEs (% of total publications)
CRS	7,962	296 (3.7%)	227 (2.9%)	42 (0.5%)	8 (0.1%)
Asthma	136,652	8,192 (6.0%)	3,370 (2.5%)	746 (0.5%)	299 (0.2%)
DM	337,411	13,633 (4.0%)	7,177 (2.1%)	2,068 (0.6%)	685 (0.2%)
p-value		χ² = 862.4; p < 0.001	χ² = 65.2; p < 0.001	χ² = 8.0; p = 0.018	χ² = 5.6; p = 0.062

CRS, chronic rhinosinusitis; RCTs, randomized controlled trials; SRs, systematic reviews; MAs, meta-analyses; EE, economic evaluations.

The bivariate analysis demonstrated that for the RCTs, there is a significant difference between CRS and asthma (3.7% vs. 6.0%; χ² = 70.6; p < 0.001) as well as asthma and DM (6.0% vs. 4.0%; χ² = 845.8; p < 0.001), but not any significant difference between the CRS and DM groups (3.7% vs. 4.0%; χ² = 2.1; p = 0.148). This indicated that the asthma literature produced the largest proportion of RCTs compared to CRS and DM.

For SRs, there is a significant difference between CRS and asthma groups (2.9% vs. 2.5%; χ² = 4.6; p = 0.032) as well as CRS and DM groups (2.9% vs. 2.1%; χ² = 19.4; p < 0.001) and asthma and DM groups (2.5% vs. 2.1%; χ² = 51.4; p < 0.001). This indicates that the CRS literature contained the largest proportion of SRs followed by asthma and then DM.

For MAs, there is no significant difference between CRS and asthma groups (0.5% vs. 0.5%; χ² = 0.5; p = 0.828), CRS and DM groups (0.5% vs. 0.6%; χ² = 0.9; p = 0.334) but there is a significant difference between asthma and DM groups (0.5% vs. 0.6%; χ2 = 7.4; p = 0.007). This indicates that the DM and CRS literature produced similar proportions of MAs to each other but a larger proportion compared to asthma.

For EEs, there is a significant difference between CRS and asthma groups (0.1% vs. 0.2%; χ2 = 4.9; p = 0.026), as well as between the CRS and DM groups (0.1% vs. 0.2%; χ2 = 4.1; p = 0.043), however no significant difference between the asthma and DM groups (0.2% vs. 0.2%; χ2 = 1.2; p = 0.279). This indicates that the DM and asthma literature produced similar proportions of EEs to each other but a larger proportion compared to CRS.

Changes in publication volume with time

When evaluating the proportion of research publications per year (between 1970 and 2014), the disparities in volume appear to be consistent over time between CRS, asthma, and DM (Figure 1A and B). There appears to be an exponential increase in the volume of CRS-related publications over the last 15 years (Figure 1C).

Figure 1

Publications per year. (A) DM vs. Asthma vs. CRS; (B) Asthma vs. CRS; (C) CRS alone.

Discussion

Measuring and reporting of medical outcomes using research publications is an important factor to drive quality improvement in health care [21,22]. This review has demonstrated a large disparity in the volume of research publications between CRS, asthma, and DM. Despite having similar prevalence rates, CRS had 6% and 2% of the publication volume compared to asthma and DM, respectively. Although there were minor differences in the proportion of high quality publications (RCTs, SRs, MAs, and EEs), the tremendous gap in overall number of publications is concerning given the fact that CRS results in similar negative impacts on quality of life [9] and economic burden [10,11] to that of asthma and DM (Table 3).

Table 3

Utility, DALY, and economic comparisons between CRS, asthma and DM

Chronic disease	Health state utility (SF-6D derived)	Disability weight	Annual direct health care cost	Annual indirect cost
CRS	0.65 [9]	Not defined	․3,143/patient [23]	^a․10,500/patient [10]
Asthma	0.70 [19]	^b0.009 [24]	․4,081/patient [25]	^d․5,846/patient [25]
Asthma	0.70 [19]	^c0.027 [24]	․4,081/patient [25]	^d․5,846/patient [25]
DM	0.68 [20]	0.015 [26]	․7,900/patient [27]	․3,920/patient [27]

(Note: all values were adjusted with an inflation calculator to reflect 2014 USD).

DALY, disability adjusted life years; CRS, chronic rhinosinusitis; DM, diabetes mellitus; SF, short-form.

^aThis indirect cost reflects patients with refractory CRS who were recruited from a tertiary level centre and likely over-estimates the mean indirect cost for all patients with CRS.

^bThis is the disability weight for ‘controlled asthma’.

^cThis is the disability weight for ‘partially controlled asthma’.

^dThis indirect cost reflects patients with severe asthma and likely overestimates the mean indirect cost for all patients with asthma.

Research priority setting has focused on burden of disease to justify resource allocation [5,6]. However, without adequate support and awareness, certain medical conditions may be inappropriately under-researched relative to its burden of disease on society. Based on the outcomes from this study, CRS is an example of a highly prevalent chronic condition that is being under-researched given its well-documented negative impacts. This raises the question of: “Why is CRS being under-researched given its large burden of disease on society?”.

Although the answer to the above question is likely multi-factorial, one important factor may be the general lack of awareness of CRS in the medical community, as was discussed in a recent article by Tan et al. titled “Chronic Rhinosinusitis: The Unrecognized Epidemic” [28]. This is highlighted by a recent multi-national study intended to quantify the burden of disease for 291 medical conditions around the globe [29]. This study evaluated common chronic diseases such as DM, asthma, coronary artery disease, hypertension, neck pain, osteoarthritis and migraine but failed to include CRS on the list of conditions. The omission of CRS from an international evaluation of burden of disease highlights the lack of awareness for this condition.

Despite CRS failing to be included in two recent multi-national studies quantifying burden of disease [29,30], the high prevalence rate should provide a strong incentive to include CRS in future discussions on research prioritization. The lowest estimate of CRS prevalence is 5%, which came from a 2003 Canadian survey of 73,364 people who were asked “if they have sinusitis diagnosed by a health professional”. Although asking patients for physician diagnosed CRS increases the sensitivity by reducing false positives, it will likely result in an underestimate due to missing people who have not sought medical care for their CRS. This is in contrast to the highest estimate of 12% from the 2014 US National Health Interview Survey (NHIS) which asked patients if they had ‘sinusitis’ rather then asking specifically about whether or not a physician diagnosed their sinusitis. The estimate from the US study will be more specific by increasing the true negative rate, however, it may include false positives such as patients with acute rhinosinusitis or other non-sinus diseases that mimic CRS such as migraines. In 2011 the Global Allergy and Asthma European Network (GA²LEN) applied a strict symptom-based approach using the European Position Paper on Rhinosinusitis and nasal Polyps (EP³OS) diagnostic criteria to estimate the prevalence of CRS in Europe. This study surveyed 57,128 people from 12 European countries and demonstrated the mean prevalence of CRS was 10.9% (range: 6.9 to 27.1%). Using the strict EP³OS symptom-based diagnostic criteria will reduce the false positive rate while maximizing the true negative rate thus increasing both the specificity and sensitivity of the CRS prevalence. Despite the inherent challenges with providing an exact prevalence estimate, the true prevalence rate for CRS in North America and Europe likely falls between 5% and 12% which is similar to asthma and DM (Table 1).

In addition to overall prevalence, the associations between CRS and reduced quality of life and economic burden are other important factors to consider. When comparing health state utility values of patients living with CRS, asthma and DM, the values appear to be similar when using the SF-6D instrument (Table 3). Furthermore, when considering the direct and indirect costs of each of these chronic diseases, DM appears to have larger direct health care costs compared to CRS, however, the indirect cost of refractory CRS is substantially higher then DM. The differences between direct and indirect costs of CRS and DM may reflect increased public awareness of DM resulting in patients seeking more medical therapy. As opposed to CRS, which may not have the same public or physician awareness and result in a substantial proportion of the population failing to receive appropriate medical treatments. The disparities in direct and indirect health care costs between CRS, asthma, and DM warrant future research.

A second potential reason for the disparity in publication volume may include a perception that CRS is a sub-specialty topic, which makes it challenging to publish research in higher impact journals that have a broader audience. This perception may deter basic science, clinical, or pharmacoeconomic researchers from adopting CRS as their academic focus despite tremendous opportunities to provide meaningful contributions. Thirdly, as opposed to CRS, untreated cases of asthma and DM may result in mortality. Although CRS has similar QoL reductions and indirect costs, the difference in mortality risk may have lead researchers to focus on asthma and DM. Lastly, there are fewer rhinologists to perform CRS research compared to the number of general internists, endocrinologists, or pulmonologists, who perform research for asthma and DM. However, given that CRS represents 1-2% of primary care physician visits [23,31], is associated with comorbid allergies in 20 to 60% of cases [32,33], and is commonly associated with asthma outcomes [34,35], CRS research should not only be conducted by rhinologists, but by primary care physicians, allergists, pulmonologists, and general internists. Efforts to increase awareness for the importance of CRS to these medical specialties may help reduce the disparity in publications

This article was intended to evaluate the overall disparities in publication volume between CRS, asthma, and DM. One limitation of this study is the inclusion of one biomedical database (Ovid MEDLINE) which may result in missing certain publications from each category of chronic disease. However, when the EMBASE database was included in the initial search it yielded the same proportion of publication volume, with CRS containing 2% and 6% of the total publication volume as DM and asthma, respectively. Thus, to keep the search strategy and outcomes simple and reproducible, one database was searched to highlight the disparities in publication volume.

Conclusion

This review has demonstrated a large disparity in the volume of published research for CRS compared to asthma and DM. Given the similarities in prevalence rates, impact on quality of life and economic burden, the relative under supply of research should prompt efforts to improve research prioritization for CRS. Future research should not only begin to elucidate factors contributing to this gap in research volume, but also begin to develop innovative strategies to increase disease awareness for the importance of CRS on population health.

Footnotes

Competing interests The author declares the he has no competing interests.

References

Canadian Institutes of Health Research (CIHR). Mandate. http://www.cihr-irsc.gc.ca/e/7263.html. Accessed Jan.2, 2015.

National Institutes of Health (NIH). Mission Statement. http://www.nih.gov/about/mission.htm. Accessed Jan.2, 2015.

National Institute for Clinical Excellence (NICE). http://www.nice.org.uk/about/what-we-do. Accessed Jan.2, 2015.

Fleurence

Setting priorities for research: a practical application of ‘payback’ and expected value of information

Health Econ 2007 16 12 1345 57 10.1002/hec.1225

17328053

Fleurence

Torgerson

Setting priorities for research

Health Policy 2004 69 1 1 10 10.1016/j.healthpol.2003.11.002

15484602

Gross

Anderson

Powe

The relation between funding by the National Institutes of Health and the burden of disease

N Engl J Med 1999 340 24 1881 7 10.1056/NEJM199906173402406 1:STN:280:DyaK1M3otVSnsA%3D%3D 10369852

Lamarre-Cliche

Castilloux

LeLorier

Association between the burden of disease and research funding by the Medical Research Council of Canada and the National Institutes of Health. A cross-sectional study

Clin Invest Med 2001 24 2 83 9 1:STN:280:DC%2BD3M3nsFygsA%3D%3D 11368150

Halawi

Smith

Chandra

Chronic rhinosinusitis: epidemiology and cost

Allergy Asthma Proc 2013 34 4 328 34 10.2500/aap.2013.34.3675

23883597

Soler

Wittenberg

Schlosser

Mace

Smith

Health state utility values in patients undergoing endoscopic sinus surgery

Laryngoscope 2011 121 12 2672 8 10.1002/lary.21847

3232034

22034223

10.

Rudmik

Smith

Schlosser

Hwang

Mace

Soler

Productivity costs in patients with refractory chronic rhinosinusitis

Laryngoscope 2014 124 9 2007 12 10.1002/lary.24630

24619604

11.

Bhattacharyya

Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States

Ann Otol Rhinol Laryngol 2011 120 7 423 7 10.1177/000348941112000701

21859049

12.

Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital and health statistics. Series 10, Data from the National Health Survey. Feb 2014(260):1–161.

13.

Chen

Dales

Lin

The epidemiology of chronic rhinosinusitis in Canadians

Laryngoscope 2003 113 7 1199 205 10.1097/00005537-200307000-00016

12838019

14.

Hastan

Fokkens

Bachert

Newson

Bislimovska

Bockelbrink

Chronic rhinosinusitis in Europe--an underestimated disease. A GA(2)LEN study

Allergy 2011 66 9 1216 1223 10.1111/j.1398-9995.2011.02646.x 1:STN:280:DC%2BC3Mfjt1KgsA%3D%3D 21605125

15.

Prevalence of Asthma. Statistics Canada. 2014; http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2012/asthma-and-copd-prevalence_9789264183896-19-en. Accessed Jan.2, 2015.

16.

OECD. Asthma Prevalence in Europe. 2014; http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2012/asthma-and-copd-prevalence_9789264183896-19-en. Accessed Jan.2, 2015.

17.

Prevalence of Diabetes Mellitus. Statistics Canada. 2014; http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health54b-eng.htm. Accessed Jan.2, 2015.

18.

OECD. Diabetes Mellitus Prevalence in Europe. 2014; http://www.oecd-ilibrary.org/sites/9789264183896-en/01/14/index.html?contentType=&itemId=%2Fcontent%2Fchapter%2F9789264183896-17-en&mimeType=text%2Fhtml&containerItemId=%2Fcontent%2Fserial%2F23056088&accessItemIds=%2Fcontent%2Fbook%2F9789264183896-en. Accessed Jan.2, 2015.

19.

Joore

Brunenberg

Nelemans

Wouters

Kuijpers

Honig

The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies

Value Health 2010 13 2 222 229 10.1111/j.1524-4733.2009.00669.x

19878492

20.

Kontodimopoulos

Pappa

Papadopoulos

Tountas

Niakas

Comparing SF-6D and EQ-5D utilities across groups differing in health status

Qual Life Res Int J Qual Life Asp Treat Care Rehab 2009 18 1 87 97 10.1007/s11136-008-9420-8

21.

Berwick

James

Coye

Connections between quality measurement and improvement

Med Care 2003 41 1 Suppl I30 8

12544814

22.

Wolpert

For the sake of inquiry and knowledge–the inevitability of open access

N Engl J Med 2013 368 9 785 7 10.1056/NEJMp1211410 1:CAS:528:DC%2BC3sXjslaks7s%3D 23445088

23.

Bhattacharyya

Orlandi

Grebner

Martinson

Cost burden of chronic rhinosinusitis: a claims-based study. Otolaryngology–head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck

Surgery 2011 144 3 440 5

24.

WHO. Disability weights 2010. http://ghdx.healthdata.org/record/global-burden-disease-study-2010-gbd-2010-disability-weights. Accessed Jan. 2, 2015.

25.

Cisternas

Blanc

Yen

Katz

Earnest

Eisner

A comprehensive study of the direct and indirect costs of adult asthma

J Allergy Clin Immunol 2003 111 6 1212 1218 10.1067/mai.2003.1449

12789219

26.

WHO. Disability weights 2004. http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf. Accessed Jan.2, 2015.

27.

Yang

Dall

Halder

Gallo

Kowal

Hogan

Economic costs of diabetes in the U.S. in 2012

Diabetes Care 2013 36 4 1033 1046 10.2337/dc12-0227

28.

Tan

Kern

Schleimer

Schwartz

Chronic rhinosinusitis: the unrecognized epidemic

Am J Respir Crit Care Med 2013 188 11 1275 7 10.1164/rccm.201308-1500ED

3919079

24289768

29.

Murray

Vos

Lozano

Naghavi

Flaxman

Michaud

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

Lancet 2012 380 9859 2197 2223 10.1016/S0140-6736(12)61689-4

23245608

30.

WHO. Global Health Observatory. 2014; http://www.who.int/gho/mortality_burden_disease/daly_rates/en/. Accessed Jan. 2, 2015.

31.

Sharp

Denman

Puumala

Leopold

Treatment of acute and chronic rhinosinusitis in the United States, 1999–2002

Arch Otolaryngol Head Neck Surg 2007 133 3 260 5 10.1001/archotol.133.3.260

17372083

32.

Schlosser

The pathophysiology of chronic rhinosinusitis

Int Forum Allergy Rhinol 2014 4 3 169 70 10.1002/alr.21317

24596322

33.

Wilson

McMains

Orlandi

The association between allergy and chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations

Int Forum Allergy Rhinol 2014 4 2 93 103 10.1002/alr.21258

24395734

34.

Frieri

Asthma linked with rhinosinusitis: An extensive review

Allergy Rhinol (Providence) 2014 5 1 41 9 10.2500/ar.2014.5.0083

35.

Vashishta

Soler

Nguyen

Schlosser

A systematic review and meta-analysis of asthma outcomes following endoscopic sinus surgery for chronic rhinosinusitis

Int Forum Allergy Rhinol 2013 3 10 788 94 10.1002/alr.21182

23818462